Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease

Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):140-6. doi: 10.1016/j.molbrainres.2003.08.005.

Abstract

By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. Two-dimensional gel electrophoresis (2-DE), SYPRO Ruby staining and mass spectrometry were used for clinical screening of disease-influenced CSF proteins in AD patients compared to controls. In order to increase the detection of CSF proteins and to improve the separation of protein isoforms in a 2-D gel, micro-narrow range IPG strips were used. The levels of eight proteins and their isoforms, including apolipoprotein A1, apolipoprotein E, apolipoprotein J, beta-trace, retinol-binding protein, kininogen, alpha-1 antitrypsin, cell cycle progression 8 protein, and alpha-1beta glycoprotein were significantly altered in CSF of AD patients compared to controls. Furthermore, we also used liquid-phase IEF, as a prefractionation step, prior to 2-DE for comparison of CSF proteins between individual AD patients and controls. The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, alpha-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / diagnosis*
  • Apolipoproteins / cerebrospinal fluid
  • Biomarkers / cerebrospinal fluid
  • Cerebrospinal Fluid Proteins / analysis*
  • Electrophoresis, Gel, Two-Dimensional / methods
  • Female
  • Glycoproteins / cerebrospinal fluid
  • Humans
  • Male
  • Proteomics / methods*
  • Reference Values

Substances

  • Apolipoproteins
  • Biomarkers
  • Cerebrospinal Fluid Proteins
  • Glycoproteins